评估荷兰家族性腺瘤性息肉病相关的硬纤维瘤的治疗方法。
Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients.
机构信息
The Netherlands Foundation for the Detection of Hereditary Tumours, Rijnsburgerweg 10, Poortgebouw Zuid, 2333 AA Leiden, The Netherlands.
出版信息
Br J Cancer. 2011 Jan 4;104(1):37-42. doi: 10.1038/sj.bjc.6605997. Epub 2010 Nov 9.
BACKGROUND
The optimal treatment of desmoid tumours is controversial. We evaluated desmoid management in Dutch familial adenomatous polyposis (FAP) patients.
METHODS
Seventy-eight FAP patients with desmoids were identified from the Dutch Polyposis Registry. Data on desmoid morphology, management, and outcome were analysed retrospectively. Progression-free survival (PFS) rates and final outcome were compared for surgical vs non-surgical treatment, for intra-abdominal and extra-abdominal desmoids separately. Also, pharmacological treatment was evaluated for all desmoids.
RESULTS
Median follow-up was 8 years. For intra-abdominal desmoids (n=62), PFS rates at 10 years of follow-up were comparable after surgical and non-surgical treatment (33% and 49%, respectively, P=0.163). None of these desmoids could be removed entirely. Eventually, one fifth died from desmoid disease. Most extra-abdominal and abdominal wall desmoids were treated surgically with a PFS rate of 63% and no deaths from desmoid disease. Comparison between NSAID and anti-estrogen treatment showed comparable outcomes. Four of the 10 patients who received chemotherapy had stabilisation of tumour growth, all after doxorubicin combination therapy.
CONCLUSION
For intra-abdominal desmoids, a conservative approach and surgery showed comparable outcomes. For extra-abdominal and abdominal wall desmoids, surgery seemed appropriate. Different pharmacological therapies showed comparable outcomes. If chemotherapy was given for progressively growing intra-abdominal desmoids, most favourable outcomes occurred after combinations including doxorubicin.
背景
纤维瘤病的最佳治疗方法存在争议。我们评估了荷兰家族性腺瘤性息肉病(FAP)患者的纤维瘤病的治疗方法。
方法
从荷兰息肉病登记处确定了 78 例患有纤维瘤病的 FAP 患者。回顾性分析了纤维瘤形态、治疗和结局的数据。分别对手术与非手术治疗、腹腔内和腹腔外纤维瘤病进行了无进展生存率(PFS)和最终结局的比较。还评估了所有纤维瘤病的药物治疗。
结果
中位随访时间为 8 年。对于腹腔内纤维瘤病(n=62),10 年随访时手术和非手术治疗的 PFS 率相似(分别为 33%和 49%,P=0.163)。这些纤维瘤病都不能完全切除。最终,五分之一的患者死于纤维瘤病。大多数腹腔外和腹壁纤维瘤病采用手术治疗,PFS 率为 63%,无纤维瘤病死亡。非甾体抗炎药和抗雌激素治疗的比较显示出相似的结果。接受化疗的 10 例患者中有 4 例肿瘤生长稳定,均在多柔比星联合治疗后。
结论
对于腹腔内纤维瘤病,保守治疗和手术治疗的结果相似。对于腹腔外和腹壁纤维瘤病,手术似乎是合适的。不同的药物治疗显示出相似的结果。如果对进行性生长的腹腔内纤维瘤病进行化疗,最有利的结果发生在包括多柔比星的联合治疗后。